Ibrutinib for treating Waldenstrom's macroglobulinaemia - guidance (TA491)

National Institute for Health and Care Excellence - NICE
Publication date:
22 November 2017


Evidence-based recommendations on ibrutinib (Imbruvica) for treating Waldenstrom’s macroglobulinaemia in adults after at least 1 previous therapy.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: The guidance will be updated when the data collection period has ended (expected to be September 2020). Ibrutinib will continue to be available through the Cancer Drugs Fund while the guidance is being updated, as part of the managed access agreement.